Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Noosa News20 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers